Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutrelef for Cognition in Down Syndrome
NCT04390646Phase 3Recruiting
- Start
- Aug 2020
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 3 trial of gonadorelin in Down syndrome, No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity., Alzheimer's disease (AD), Olfactory dysfunction. Started Aug 2020; status: recruiting.
02
Drugs
gonadorelin
03
Conditions
Down syndromeNo canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.Alzheimer's disease (AD)Olfactory dysfunction
Beyond the preview
Go deeper on NCT04390646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04390646.